Amgen is asking the U.S. Supreme Court to take up a previous ruling that invalidated two key patents for its PCSK9 drug, Repatha. A federal appeals court in June declined to hear the case. This is the latest chapter in a saga that dates back to 2014, when Amgen sued Sanofi and Regeneron to protect Repatha’s patents against a competing drug, Praluent, which ultimately delayed Praluent’s launch. For the treatment of atherosclerotic cardiovascular disease (ASCVD), Repatha holds covered or better status for 85% of all insured lives under the pharmacy benefit, compared to Praluent’s 76%.
SOURCE: MMIT Analytics, as of 12/1/21